2. The Global Community Advisory Board (GCAB) is a network-level body made up of one or two CAB members from each site. The GCAB facilitates communication between CAB members and the HVTN, and its counterparts at the global level. CAB members at the local site level as well as those who serve on Network committees play a crucial role in ensuring that the concerns of their communities are being addressed by the Network. GCAB representatives are an essential link in the communication between their CAB, the site's HVTN, and the GCAB. We hope that the expectations outlined above can serve as a tool for improving the efficiency of CAB and GCAB communications.

3. Regular email communication occurs among GCAB representatives as well as with the staff of the CEU. GCAB representatives are expected to participate in these communications and meet stated deadlines for requested actions. GCAB representatives are also expected to keep their local CAB up to date on GCAB discussions and activities.

4. Following each GCAB conference call, the CAB Bulletin will be sent out via email. It is important that GCAB representatives share these minutes with their local CAB, regardless of whether he or she was able to participate on the call. If members of the local CAB do not have email access, the GCAB representative should request the site's CAB liaison person print out the minutes and share them at the next CAB meeting.

5. The CEU created a list of expectations which was shared and discussed this topic. Earlier this year, The Community Engagement Unit noticed some weak links in the chain of communication between CABs, the GCAB, and the HVTN. In order to determine if a network-level body made up of one or two CAB members from each site as well as those who serve on Network committees play a crucial role in ensuring that the concerns of their communities are being addressed by the Network. GCAB representatives are an essential link in the communication between their CAB, the site's HVTN, and the GCAB. We hope that the expectations outlined above can serve as a tool for improving the efficiency of CAB and GCAB communications.

6. Non-Language Call Lanes and Email HVTN CAB Bulletin

For Local CABs to HVTN Core: Why GCAB Representatives Are Essential!

By Carrie Schonwald, International Project Manager, Community Engagement Unit.

Why GCAB Representatives are Essential!

- participate instead. If the alternate is also not available, the site should select another person within the site or the site’s CAB liaison staff person to join the call.

- CAB members interested in working on ethical issues.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.

- CAB bulletin to: Send suggestions, questions, and submissions for the CAB Bulletin to: Lisa Donohue, Editor, lisa.donohue@hvtanetwork.org.
In the past five years the idea of PrEP has taken the HIV biomedical prevention field by storm. With PrEP, which stands for Pre-Exposure Prophylaxis, drugs originally designed to treat HIV infections are used for prevention. Recently the idea of PrEP has taken the HIV biomedical prevention field by storm. With PrEP, which stands for Pre-Exposure Prophylaxis, drugs originally designed to treat HIV infections are used for prevention.

Getting PrEPared: Results and Remaining Questions from Recent Biomedical HIV Prevention Trials

**SFPR (also called CDC 4940)**
- **Study design:** Extended safety study
- **Participants:** 2499 individuals
- **Location:** US
- **Study outcomes:** Reduced the risk of HIV infection by 42%.

**iPrEx**
- **Study design:** Phase 3 efficacy study
- **Participants:** 4758 couples
- **Locations:** Kenya, Tanzania, Brazil, Ecuador, India, Kenya, Tanzania, Zimbabwe
- **Study outcomes:** Reduced the risk of HIV infection by 36%.

**TDF2**
- **Study design:** Phase 2b safety study
- **Participants:** 350-550 individuals
- **Locations:** Thailand, US
- **Study outcomes:** Reduced the risk of HIV infection by 37%.

**Partners-PrEP**
- **Study design:** Phase 3 efficacy study
- **Participants:** 2499 individuals
- **Locations:** Kenya, Uganda
- **Study outcomes:** Reduced the risk of HIV infection by 32%.

**M465**
- **Study design:** Phase 3 safety study
- **Participants:** 2499 individuals
- **Locations:** Brazil, Ecuador, Peru, South Africa, Thailand, US
- **Study outcomes:** Reduced the risk of HIV infection by 26%.

**CWE222**
- **Study design:** Extended safety study
- **Participants:** 1950 individuals
- **Locations:** Kenya, Tanzania, South Africa
- **Study outcomes:** Reduced the risk of HIV infection by 19%.

**FN1-PREP**
- **Study design:** Phase 1 safety study
- **Participants:** 2499 individuals
- **Locations:** Brazil, India, Kenya, Malawi, South Africa, Thailand, Zimbabwe
- **Study outcomes:** Reduced the risk of HIV infection by 15%.

**HPTN 052**
- **Study design:** Phase 3 efficacy study
- **Participants:** 1950 individuals
- **Locations:** Kenya, Uganda
- **Study outcomes:** Reduced the risk of HIV infection by 13%.

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- What is the safest dose?
- Is there similar efficacy in other populations?
- Can this efficacy be replicated in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.

**Analysis ongoing – reasons for the results are not yet known.**

**Additional study questions:**
- How should such care be implemented?
- Should PrEP be effective in this population, and is such replication necessary?
- None at this time.